David White

Cable & Wireless Ltd. operates as a telecommunications company. The company was founded in 1929 and is headquartered in London, the United Kingdom.

Tesla Energy Operations, Inc. engages in the business of renewable energy services such as, solar energy products and services. The company was founded by Lyndon R. Rive and Peter J. Rive on June 21, 2006 and is headquartered in Austin, TX.

Hands-On Mobile, Inc. engages in the publication and development of social games for mobile and online platforms. Its products include games, subscription services, brand management, distribution, and porting and platform management. The firm offers global distribution brands and content from partners including activision, billboard, CBS, marvel, NBA, and world poker tour. The company was founded by Daniel Kranzler in 2001 and is headquartered in San Francisco, CA.

Chiron Corp. provides nucleic acid test for blood screening. Its products include tigris system, target capture system, reagent preparation incubator, and many more. The company was founded in 1981 by William J. Rutter, Edward E. Penhoet & Pablo Valenzuela and is headquartered in Emeryville, CA.

Digital Island, Inc. provides network services for e-business applications. The company is based in San Francisco, CA and has subsidiaries in the United States.

One Planet VC LLC (One Planet VC) is a venture capital firm subsidiary of One Planet Group Inc founded in 2015 by Payam Zamani. The firm is headquartered in Walnut creek, California.

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C.